Key result
Protein S-nitrosylation controls cardiac excitation-contraction coupling, with distinct dysregulation driving HFrEF versus HFpEF.
Why the study?
Disruption of NO bioavailability and redox balance during cardiovascular disease alters the cardiac S-nitrosoproteome, and protein S-nitrosylation exerts dual protective or detrimental effects depending on the molecular context, subcellular localization, and disease stage.
This review details how compartmentalized protein S-nitrosylation regulates cardiac excitation-contraction coupling and mitochondrial bioenergetics, highlighting how hypo-nitrosylation in HFrEF and hypernitrosylation in HFpEF drive pathological cardiac remodeling.
Answers are grounded in this paper and cite their sources.
Supports distinct redox mechanisms in HFrEF versus HFpEF; leaves open targeted therapies pending interventional validation.
Protein S-nitrosylation (SNO), a reversible nitric oxide (NO)-dependent post-translational modification to reactive cysteine residues, finely tunes cardiac excitation–contraction coupling, mitochondrial function, and stress responses. In cardiomyocytes, compartmentalized NO signaling via neuronal (nNOS), endothelial (eNOS), and inducible (iNOS) isoforms regulates SNO of key proteins (e.g., RyR2, LTCC, SERCA2a, mitochondrial Complex I). Under physiological conditions, SNO modulates Ca 2+ handling, myofilament sensitivity, and bioenergetics, while pathological SNO dysregulation, hypo-nitrosylation in heart failure (HF) with reduced ejection fraction or hypernitrosylation in HF with preserved ejection fraction, contributes to contractile dysfunction, arrhythmias, and mitochondrial impairment. Cardioprotective SNO (e.g., during ischemia-reperfusion) acts as a "redox shield", preventing irreversible oxidation of critical cysteines, whereas excessive or mislocalized SNO can be detrimental, this dynamic modification plays an essential role in maintaining cardiac function. However, disruption of NO bioavailability and redox balance during cardiovascular disease alters the cardiac S-nitrosoproteome, contributing to maladaptive signaling, mitochondrial dysfunction, contractile impairment, and pathological remodeling. Increasing evidence also highlights the dual nature of SNO exerts either protective or detrimental effects depending on the molecular context, subcellular localization, and disease stage. This review summarizes current knowledge on SNO mechanisms in the heart and discusses its roles in physiological cardiac function and major cardiac pathologies.
No takes yet. Share an insight, caveat, or question.
Gouin-Gravezat et al. (2026) conducted a review in Cardiovascular disease and heart failure (HFrEF and HFpEF). Protein S-nitrosylation (SNO) was evaluated. Protein S-nitrosylation regulates cardiac excitation-contraction coupling and bioenergetics, with hypo-nitrosylation in HFrEF and hypernitrosylation in HFpEF driving dysfunction.
Synapse has enriched 10 related papers. Consider them for comparative context: